A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

Clinical Trial ID NCT01715285

Rank	Title	Journal	Year	PubWeight™‹?›
1	Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.	N Engl J Med	2017	4.48
2	Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.	Nat Rev Cancer	2015	1.55
3	Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer.	Oncologist	2014	1.05
4	Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?	World J Urol	2014	0.92
5	Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy.	Ther Adv Urol	2015	0.88
6	Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer.	Clin Med Insights Urol	2013	0.85
7	Abiraterone in the treatment of metastatic castration-resistant prostate cancer.	Cancer Manag Res	2014	0.83
8	Chemotherapy for metastatic castrate-sensitive prostate cancer.	Prostate Cancer Prostatic Dis	2016	0.79
9	The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.	Prostate Cancer Prostatic Dis	2016	0.77